| 18.7 0.95 (5.35%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.74 | 1-year : | 26.86 |
| Resists | First : | 20.32 | Second : | 23 |
| Pivot price | 20.27  |
|||
| Supports | First : | 16 | Second : | 13.31 |
| MAs | MA(5) : | 18.36 |
MA(20) : | 20.57 |
| MA(100) : | 21.7 | MA(250) : | 19.58 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 30.3 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 29.29 | Low : | 15.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CALT ] has closed above bottom band by 24.9%. Bollinger Bands are 44.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.72 - 19.86 | 19.86 - 19.96 |
| Low: | 18.11 - 18.25 | 18.25 - 18.36 |
| Close: | 18.52 - 18.73 | 18.73 - 18.9 |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Fri, 19 Apr 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 3.4% Higher - MarketBeat
Thu, 18 Apr 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74 - MarketBeat
Wed, 17 Apr 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.80 - MarketBeat
Wed, 10 Apr 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 8.3% - MarketBeat
Thu, 21 Mar 2024
ALPMY: 3 Pharma Gems Poised for Breakthroughs - StockNews.com
Thu, 22 Feb 2024
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -38.7 % |
| Operating Margin | 7 % |
| Return on Assets (ttm) | -12.3 % |
| Return on Equity (ttm) | -84.7 % |
| Qtrly Rev. Growth | 5.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 45.08 |
| EBITDA (p.s.) | -13.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -435 (M) |
| Levered Free Cash Flow | -332 (M) |
| PE Ratio | -11.55 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.41 |
| Price to Cash Flow | -1.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|